Nivolumab before surgery for head and neck cancer
Part of Cancer, Mouth & dental clinical trials.
This study tests a specially marked version of a drug called nivolumab (an immunotherapy that helps your immune system fight cancer) given directly into the tumor before your scheduled surgery. The goal is to help researchers see how the drug works in the tumor and whether it could improve treatment for head and neck cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have head and neck cancer (confirmed by biopsy).
- You must be planning to have surgery to remove the cancer.
- You must be 18 years or older.
- You must be healthy enough for surgery and anesthesia.
- You cannot have an active autoimmune disease or a history of certain immune system conditions (except for a few like well-controlled thyroid disease or type 1 diabetes).
- You cannot be pregnant, breastfeeding, or planning to become pregnant during the study or for 5 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a special dye attached to the drug nivolumab can help surgeons see cancer cells more clearly during surgery. If you have head and neck cancer and are scheduled for surgery, this study might be an option for you.
This trial tests a combination of an immunotherapy drug (tirelizumab) with two chemotherapy drugs before surgery for head and neck cancer that has spread to lymph nodes. The goal is to shrink the tumor and improve treatment outcomes.
This trial tests a combination of immune therapy, targeted drugs, and a virus-based treatment before surgery for head and neck cancer that has spread to lymph nodes. The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial tests a combination of two immunotherapy drugs (pembrolizumab and N-803) with or without special immune cells (PD-L1 t-haNK cells) before surgery for head and neck cancer. The goal is to see if this treatment can shrink the cancer or improve the outcome after surgery.
This trial tests giving a combination of two drugs (an immunotherapy drug called a PD-1 inhibitor and a targeted therapy called cetuximab) before surgery to shrink head and neck cancers. The goal is to see if this approach lowers the chance of the cancer coming back after surgery.
This trial tests whether giving tislelizumab (an immunotherapy) with chemotherapy before surgery works better than surgery alone for people with head and neck cancer that has not spread to lymph nodes. It's for cancers that can be removed with surgery, and the goal is to see if the pre-surgery treatment improves outcomes.
Hear when a new HNSCC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.